chartexchange

IBRX261120C00007000
IBRX Nov 20 2026 7.00 Call
optionOPRA

EODOct 16, 2026
2.40USD38Vol1,112OI
Loading…
Underlying
Underlying Price
$8.28
Type
Call
Strike
7
Expiration
Nov 20, 2026
DTE
31d
Moneyness
ITM
Intrinsic
$1.28
IBRX 7 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$3.00+0.00%1011
Oct 30, 202610d$3.76+34.29%711
Nov 6, 202617d$3.28-9.64%14
Nov 13, 202624d——00
Nov 20, 202631d$2.40-29.82%381,112
Nov 27, 202638d——00
Dec 18, 202659d——00
Mar 19, 2027150d$4.03-4.05%1255
Apr 16, 2027178d$4.48+0.00%1111
May 21, 2027213d$4.30-4.44%586
Aug 20, 2027304d$3.90-20.41%6252
Nov 19, 2027395d$5.40+14.89%104130
Mar 17, 2028514d$5.20+4.84%20890
Jan 19, 2029822d$5.80-4.92%1105
IBRX Nearby Strikes · Nov 20, 2026
StrikeLastChangeVolOpen IntMoneyness
1 C$8.65-5.98%144ITM
2 C$7.67+43.36%2021ITM
3 C$6.41-7.90%2161ITM
4 C$5.45-12.10%1648ITM
5 C$4.85-6.73%43ITM
6 C$3.50-12.50%53147ITM
7 C$2.40-29.82%381,112ITM
8 C$1.75-28.57%1291,390ITM
9 C$1.10-38.89%406,064OTM
10 C$0.80-38.46%3116,043OTM
11 C$0.55-37.50%6305,915OTM
12 C$0.36-40.00%1977,831OTM
13 C$0.25-39.02%21,184OTM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.